# MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
Canonical URL: https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance
Ticker: MXCT
Company: MaxCyte
Source: MaxCyte
Published: 2026-05-12 20:06 EST
Original Source URL: https://investors.maxcyte.com
## Summary

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

## Article Body
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million
## Recent Company News
- 2026-05-12 20:06 EST — [MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance) — Source: MaxCyte
- 2026-04-29 20:05 EST — [MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026](https://biopharmsignal.com/news/MXCT/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026) — Source: MaxCyte
- 2026-03-31 20:05 EST — [MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MXCT/maxcyte-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: MaxCyte
- 2026-03-24 20:05 EST — [MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-guidance) — Source: MaxCyte
- 2026-03-23 12:05 EST — [MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer](https://biopharmsignal.com/news/MXCT/maxcyte-appoints-parmeet-ahuja-as-chief-financial-officer) — Source: MaxCyte
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)